D.E. Shaw & Co’s Avadel Pharmaceuticals AVDL Stock Holding History

D.E. Shaw & Co’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-64,300	Closed	-$1.39M	–	4533
2025 Q4	$1.39M	Buy	64,300 +21,400	+50%	+$415K	﹤0.01%	3325
2025 Q3	$655K	Buy	+42,900	New	+$558K	﹤0.01%	3714
2025 Q1	–	Sell	-34,900	Closed	-$367K	–	4242
2024 Q4	$367K	Buy	34,900 +200	+0.6%	+$2.43K	﹤0.01%	3790
2024 Q3	$455K	Buy	34,700 +4,700	+16%	+$71.6K	﹤0.01%	3753
2024 Q2	$422K	Buy	+30,000	New	+$489K	﹤0.01%	3730

Other funds holding AVDL

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

D.E. Shaw & Co's AVDL Position: Q1 2026 in Review

D.E. Shaw & Co sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 132,459 shares — an estimated $2.85M sold.

D.E. Shaw & Co first reported a position in AVDL in Q2 2014 and held it in 41 quarters. The position peaked at $12.6M in Q2 2023. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

D.E. Shaw & Co reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
D.E. Shaw & Co sold 132,459 Avadel Pharmaceuticals shares in Q1 2026, an estimated $2.85M.
D.E. Shaw & Co first reported a position in Avadel Pharmaceuticals in Q2 2014 and held it in 41 quarters.
D.E. Shaw & Co's Avadel Pharmaceuticals position peaked at $12.6M in Q2 2023.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.